GSK's Linerixibat Granted Priority Review in China for Cholestatic Pruritus in PBC
Summary
GSK announced that its new drug application for linerixibat, targeting cholestatic pruritus in primary biliary cholangitis (PBC), has been accepted for priority review by China's National Medical Products Administration.
Key Events
-
Priority Review Granted in China
Linerixibat, an investigational drug for cholestatic pruritus in primary biliary cholangitis (PBC), has been accepted for priority review by China's National Medical Products Administration.
-
Addresses Significant Unmet Need
Cholestatic pruritus in PBC is a serious and debilitating condition affecting approximately 280,000 people in China, with few effective treatment options.
-
Based on Positive Phase III Data
The application is supported by positive data from the GLISTEN phase III trial, which demonstrated significant and sustained improvement in pruritus and sleep interference.
-
Global Regulatory Progress
Marketing applications for linerixibat are also currently under Health Authority review in the US, EU, UK, and Canada, with Orphan Drug Designation already granted in the US, EU, and Japan.
Analysis
GSK's investigational drug, linerixibat, receiving priority review in China is a significant positive development. This accelerates the regulatory pathway in a substantial market, as China has a large patient population suffering from primary biliary cholangitis (PBC) and associated cholestatic pruritus, a debilitating condition with limited treatment options. The priority review status, based on positive Phase III trial data, indicates regulatory confidence and brings the drug closer to potential commercialization. This milestone, alongside ongoing reviews in other major markets, strengthens GSK's hepatology pipeline and could contribute meaningfully to future revenue, especially as the company's stock is currently trading near its 52-week high.
At the time of this filing, GSK was trading at $59.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $121B. The 52-week trading range was $32.38 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.